{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:35:04Z","timestamp":1791282904606,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11607-w","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T10:43:53Z","timestamp":1759833833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of drug resistance mutations and their association with time to virological failure in people living with HIV in Uganda"],"prefix":"10.1186","volume":"25","author":[{"given":"Collins","family":"Ankunda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Emunyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Namasambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Sserunjogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendah","family":"Kyomuhangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iving","family":"Mumbere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Nakaweesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"11607_CR1","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/S1473-3099(17)30482-6","volume":"18","author":"N Ford","year":"2018","unstructured":"Ford N, Ball A, Baggaley R, Vitoria M, Low-Beer D, et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead. Lancet Infect Dis. 2018;18:e76\u201386.","journal-title":"Lancet Infect Dis"},{"key":"11607_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13643-020-01524-1","volume":"9","author":"Y Lailulo","year":"2020","unstructured":"Lailulo Y, Kitenge M, Jaffer S, Aluko O, Nyasulu PS. Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis. Syst Rev. 2020;9:292.","journal-title":"Syst Rev"},{"key":"11607_CR3","first-page":"1035","volume":"13","author":"A Shumetie","year":"2021","unstructured":"Shumetie A, Moges NA, Teshome M, Gedif G. Determinants of virological failure among HIV-Infected children on First-Line antiretroviral therapy in West Gojjam zone, Amhara region, Ethiopia. HIVAIDS Auckl NZ. 2021;13:1035\u201344.","journal-title":"HIVAIDS Auckl NZ"},{"key":"11607_CR4","doi-asserted-by":"crossref","unstructured":"Cao P, Su B, Wu J, Wang Z, Yan J et al. (2018) Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: An observational cohort study. Medicine (Baltimore) 97. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6076136\/. Accessed 24 April 2023.","DOI":"10.1097\/MD.0000000000011463"},{"key":"11607_CR5","unstructured":"WHO releases HIV drug resistance report. 2021 (n.d.). Available: https:\/\/www.who.int\/news\/item\/24-11-2021-who-releases-hiv-drug-resistance-report-2021. Accessed 13 May 2022."},{"key":"11607_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","volume":"380","author":"RK Gupta","year":"2012","unstructured":"Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet Lond Engl. 2012;380:1250\u20138.","journal-title":"Lancet Lond Engl"},{"key":"11607_CR7","unstructured":"MoH. (2018) Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Minist Health Uganda: 142\u201370."},{"key":"11607_CR8","unstructured":"Identification of fast. -spreading HIV variant provides evidence of urgency to halt the pandemic and reach all with testing and treatment | UNAIDS (n.d.). Available: https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2022\/february\/20220207_hiv-variant. Accessed 18 April 2022."},{"key":"11607_CR9","unstructured":"Consolidated guidelines for the prevention and treatment of HIV and AIDS in. Uganda, November 2022 | GPC (n.d.). Available: https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/consolidated-guidelines-prevention-and-treatment-hiv-and-aids-uganda-november-2022. Accessed 22 November 2024."},{"key":"11607_CR10","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1093\/jac\/dkab159","volume":"76","author":"C Watera","year":"2021","unstructured":"Watera C, Ssemwanga D, Namayanja G, Asio J, Lutalo T, et al. HIV drug resistance among adults initiating antiretroviral therapy in Uganda. J Antimicrob Chemother. 2021;76:2407.","journal-title":"J Antimicrob Chemother"},{"key":"11607_CR11","unstructured":"Mildmay Uganda | Empowering Communities for Healthier Lives. (n.d.). Available: https:\/\/mildmay.or.ug\/. Accessed 24 April 2023."},{"key":"11607_CR12","unstructured":"HIV DR |Login. (n.d.). Available: https:\/\/hivdr.cphluganda.org\/userAuth\/login. Accessed 6 November 2024."},{"key":"11607_CR13","unstructured":"Weir CB, Jan A. (2025) BMI Classification Percentile And Cut Off Points. StatPearls. Treasure Island (FL): StatPearls Publishing. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541070\/. Accessed 3 May 2025."},{"key":"11607_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1742-6405-10-30","volume":"10","author":"G Ramjee","year":"2013","unstructured":"Ramjee G, Daniels B. Women and HIV in Sub-Saharan Africa. AIDS Res Ther. 2013;10:30.","journal-title":"AIDS Res Ther"},{"key":"11607_CR15","unstructured":"Consolidated. guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach (n.d.). Available: https:\/\/www.who.int\/publications-detail-redirect\/9789240031593. Accessed 17 March 2024."},{"key":"11607_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/QAI.0000000000002689","volume":"87","author":"C Bossard","year":"2021","unstructured":"Bossard C, Schramm B, Wanjala S, Jain L, Mucinya G, et al. High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients.High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients.. J Acquir Immune Defic Syndr. 2021;87:883.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11607_CR17","first-page":"156","volume":"19","author":"VA Johnson","year":"2016","unstructured":"Johnson VA, Calvez V, G\u00fcnthard HF, Paredes R, Pillay D, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2016;19:156\u201364.","journal-title":"Top Antivir Med"},{"key":"11607_CR18","unstructured":"HIV Drug Resistance Database. (n.d.). Available: https:\/\/hivdb.stanford.edu\/. Accessed 21 April 2022."},{"key":"11607_CR19","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1128\/jvi.67.4.2412-2420.1993","volume":"67","author":"PL Boyer","year":"1993","unstructured":"Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1993;67:2412.","journal-title":"J Virol"},{"key":"11607_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1006\/jmbi.2001.4648","volume":"309","author":"Y Hsiou","year":"2001","unstructured":"Hsiou Y, Ding J, Das K, Clark AD, Boyer PL, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol. 2001;309:437\u201345.","journal-title":"J Mol Biol"},{"key":"11607_CR21","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","volume":"47","author":"K Diallo","year":"2003","unstructured":"Diallo K, G\u00f6tte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2003;47:3377.","journal-title":"Antimicrob Agents Chemother"},{"key":"11607_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1074\/jbc.M308806200","volume":"279","author":"J Deval","year":"2004","unstructured":"Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations**. J Biol Chem. 2004;279:509\u201316.","journal-title":"J Biol Chem"},{"key":"11607_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72:e1.","journal-title":"Drugs"},{"key":"11607_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/pathogens14010048","volume":"14","author":"N Ismael","year":"2025","unstructured":"Ismael N, Hussein C, Magul C, Inguane H, Couto A, et al. HIV drug resistance profile in clients experiencing treatment failure after the transition to a Dolutegravir-Based First-Line antiretroviral treatment regimen in Mozambique. Pathogens. 2025;14:48.","journal-title":"Pathogens"},{"key":"11607_CR25","doi-asserted-by":"crossref","unstructured":"Zenebe E, Washo A, Addis Gesese A. (2021) Time to First-Line Antiretroviral Treatment Failure and Its Predictors among HIV-Positive Children in Shashemene Town Health Facilities, Oromia Region, Ethiopia, 2019. Sci World J 2021: 8868479.","DOI":"10.1155\/2021\/8868479"},{"key":"11607_CR26","doi-asserted-by":"publisher","first-page":"e0275204","DOI":"10.1371\/journal.pone.0275204","volume":"17","author":"DE Andarge","year":"2022","unstructured":"Andarge DE, Hailu HE, Menna T. Incidence, survival time and associated factors of virological failure among adult HIV\/AIDS patients on first line antiretroviral therapy in st. Paul\u2019s hospital millennium medical College\u2014A retrospective cohort study. PLoS ONE. 2022;17:e0275204.","journal-title":"PLoS ONE"},{"key":"11607_CR27","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for. treating and preventing HIV infection: recommendations for a public health approach, 2nd ed (n.d.). Available: https:\/\/www.who.int\/publications-detail-redirect\/9789241549684. Accessed 17 March 2024."},{"key":"11607_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMc1716089","volume":"378","author":"HIV Drug Resistance","year":"2018","unstructured":"HIV Drug Resistance. N Engl J Med. 2018;378:873\u20135.","journal-title":"N Engl J Med"},{"key":"11607_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/09540121.2015.1124984","volume":"28","author":"L Zhang","year":"2016","unstructured":"Zhang L, Li X, Lin Z, Jacques-Tiura AJ, Xu J, et al. Side effects, adherence self-efficacy, and adherence to antiretroviral treatment (ART): A mediation analysis in a Chinese sample. AIDS Care. 2016;28:919.","journal-title":"AIDS Care"},{"key":"11607_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/aid.2015.0296","volume":"32","author":"A Mujugira","year":"2016","unstructured":"Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N, et al. Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-Infected persons in serodiscordant partnerships. AIDS Res Hum Retroviruses. 2016;32:148\u201354.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"11607_CR31","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1007\/s10461-022-03610-y","volume":"26","author":"CD Agegnehu","year":"2022","unstructured":"Agegnehu CD, Techane MA, Mersha AT, Atalell KA. Burden and associated factors of virological failure among people living with HIV in Sub-Saharan africa: A systematic review and Meta-Analysis. AIDS Behav. 2022;26:3327\u201336.","journal-title":"AIDS Behav"},{"key":"11607_CR32","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1186\/s12879-022-07692-w","volume":"22","author":"G Musengimana","year":"2022","unstructured":"Musengimana G, Umugisha JP, Habinshuti P, Anderson T, Mukesharurema G, et al. Characteristics and clinical outcomes of patients presenting with advanced HIV disease in the treat all era: a retrospective cohort study from rural Rwanda. BMC Infect Dis. 2022;22:706.","journal-title":"BMC Infect Dis"},{"key":"11607_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fendo.2018.00705","volume":"9","author":"S Kumar","year":"2018","unstructured":"Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of Pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol. 2018;9:705.","journal-title":"Front Endocrinol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11607-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T10:43:58Z","timestamp":1759833838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11607-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11607"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11607-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6606593\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Mildmay Uganda Research Ethics Committee (#REC REF 0201\u20132024) and then Uganda National Council for Science and Technology (HS3873ES). A waiver of informed consent was granted by Mildmay Uganda Research Ethics Committee for the use of de-identified retrospective data. Administrative clearance was sought from MUgH administration to access participant data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1241"}}